Atossa Genetics Featured on FoxNews.com

SEATTLE, WA--(Marketwired - Sep 12, 2013) - The ForeCYTE Breast Health Test, the flagship product of Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, was featured in a video segment and article on FoxNews.com posted on September 11.

The segment and article profiled Marci Dulgerian, a resident of Little Neck, NY who lost both her mother and grandmother to breast cancer, and who wants more information about her breast health. During the segment, Ms. Dulgerian's OB/GYN, Dr. Jonathan Herman of Elite Women's Healthcare in New Hyde Park, NY, recommends that Ms. Dulgerian undergo the ForeCYTE test.

"Why would someone choose to become another victim to breast cancer when this test can give them all the information they need to save their life?" asks Ms. Dulgerian during the segment.

"It's a helper for your mammography," remarks Dr. Herman during the segment. "It's a helper for your breast exam, and it's a helper for your breast ultrasound -- and a helper for a history."

"Breast cancer has a peak age group of about 45 to 60, so really the younger women -- the 20-, 30- and maybe 40-year-old -- is the ideal population for this," says Steven C. Quay, M.D., Ph.D., FCAP, Chairman, President and Chief Executive Officer of Atossa Genetics, during the segment. "Most mammograms begin at 40 or sometimes as early as 35, but definitely in an older age group."

To view the FoxNews.com segment and read the story, please visit the following link:
http://www.foxnews.com/health/2013/09/11/new-test-can-help-detect-breast-cancer-decade-before-it-develops/

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. The test can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit getforecyte.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit www.atossagenetics.com. For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.